Mediaclew facilitates the strategic acquisition and transition of category-defining digital assets.

We specialize in high-stakes domain infrastructure for the Life Sciences, AI, and MedTech sectors. Our dual-mission focuses on securing underutilized, high-value assets through discreet, off-market transactions and aligning these premier identities with global industry leaders.

By operating at the intersection of corporate development and digital identity, we ensure total confidentiality, institutional-grade security, and seamless execution for both the acquisition of new portfolio assets and the divestiture of established category-killers.

Strategic Portfolio Highlights:

CellFreeDNA.com | Precision Oncology & Liquid Biopsy
The definitive category-killer for the non-invasive genomic testing market.

TissueDynamics.com | Digital Pathology & AI Diagnostics
A premier identity for the intersection of computational pathology and spatial biology.

TargetEnrichment.com | NGS Workflow & Genomic Analysis
A foundational asset for companies specializing in library preparation and selective DNA/RNA sequencing.

ClinicalBiobank.com | Specimen Logistics & Precision Medicine
A Tier-1 infrastructure domain for centralized human biospecimen management and longitudinal data storage.

AdmeTesting.com | Pharmacokinetics & Drug Development
The primary gateway for CROs and BioPharma firms focused on Absorption, Distribution, Metabolism, and Excretion (ADME) profiling.

MediaClew

Org chart

Teams

Offices

MediaClew

Org chart

Teams

Offices

Related companies